Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.
Shandong Xinhua Pharmaceutical Company Limited has announced the completion of the enrollment of the first patient in China for Phase II clinical trials of their OAB-14 dry suspension, a new chemical drug aimed at treating mild to moderate Alzheimer’s disease. This milestone signifies a significant step in the company’s research and development efforts, potentially enhancing its position in the pharmaceutical industry and offering promising implications for stakeholders interested in Alzheimer’s treatment advancements.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the development and production of innovative chemical drugs. Its primary market focus includes treatments for various diseases, with a notable emphasis on Alzheimer’s disease.
Average Trading Volume: 4,748,956
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.57B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue